Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma

The combination of isatuximab and pomalidomide plus dexamethasone (Pd) extended progression-free survival (PFS) to 11.5 months in patients with relapsed/refractory multiple myeloma (MM) –...
On location

Guadecitabine Performs No Better Than Other Hypomethylating Agents in Treatment-Naïve Acute Myeloid Leukemia

Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients with treatment-naïve acute myeloid leukemia (AML) show that this...
On location

Valoctocogene Roxaparvovec Continues to Improve Bleeding Outcomes in Patients with Hemophilia A

In three-year follow-up results from an ongoing phase I/II study of patients with hemophilia A, valoctocogene roxaparvovec gene therapy significantly reduced annual bleeding rates...
On location

Allogeneic or Autologous Transplant for Peripheral T Cell Lymphoma?

In a final analysis from the Autologous or Allogeneic Transplantation in T-Cell Lymphoma (AATT) trial, researchers found no differences in survival outcomes between consolidation...
On location

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

In a phase III trial of patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing comorbidities, a fixed-duration regimen of obinutuzumab plus venetoclax...
On location

Daratumumab Combination Induces High Response Rates in AL Amyloidosis

In one-year follow-up data from the phase III ANDROMEDA trial, the combination of subcutaneous daratumumab with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) led to high...
On location

Erythropoietin Increases Hemoglobin and Reticulocyte Counts in Patients with Treatment-Refractory AIHA

In patients with autoimmune hemolytic anemia (AIHA) unresponsive to ongoing and/or prior therapies, treatment with erythropoietin (EPO) effectively increased hemoglobin (Hb) and reticulocyte counts,...
On location

Single-Agent Ibrutinib Improves Survival and Prolongs Time to Next Treatment in Early-Stage CLL

In the double-blind, randomized CLL12 trial, patients with treatment-naïve, early-stage chronic lymphocytic leukemia (CLL) who received single-agent ibrutinib had longer event-free survival (EFS), progression-free...
On location

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
On location

Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis

In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children with blastic plasmacytoid dendritic cell neoplasm,...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.